Connect with us

USAQ: Strong Fundamental Growth, Strong Industry Trends, and Strong Technicals Line Up

New Opportunity:  USA Equities Corp (OTCMKTS:USAQ) One of the defining trends that will drive a major part of the economy over the next decade is the decentralization of the healthcare system. Home health spending, an excellent measure of this trend,…

Published

3 years ago

on

New Opportunity:  USA Equities Corp (OTCMKTS:USAQ)

One of the defining trends that will drive a major part of the economy over the next decade is the decentralization of the healthcare system.

Home health spending, an excellent measure of this trend, is expected increase at a faster rate through 2027 than all other categories of care, according to a recent analysis from the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary.

It is expected to reach more than $186 billion in 2027, according to the report. This is miles above any other category of health care service, including hospital inpatient care, physician and professional services, nursing facilities, prescription drugs, retail sales of medical products and literally everything else in the space.

That growth reflects one simple point: that the economics of the traditional hospital model for healthcare has toppled from its own weight.

The pandemic simply accelerated this trend, driving the healthcare decentralization trend into a rapid acceleration, boosting telehealth, home healthcare, and the consolidation of medical offices into larger outpatient care centers offering ambulatory surgery centers, urgent cares and sophisticated diagnostic and treatment facilities.

At the center of this constellation of concepts is a striking opportunity for new healthcare technology solutions that help to reshape the relationship between patients and providers to take full advantage of the greater efficiency on offer as this landscape evolves.

One company now at the heart of this transformative opportunity is USA Equities Corp (OTCMKTS:USAQ), a Medical Technology SaaS focused holding company that equips physicians with the digital solutions needed to increase revenues through value-based tools that evaluate and treat chronic disease, producing greater efficiency, better outcomes, and stronger unit economics.

 

Symbol:  USAQ
Company:  USA Equities Corp
Quote:  http://finance.yahoo.com/q?s=USAQ
Latest News:  http://finance.yahoo.com/q/h?s=USAQ+Headlines
Company Website: www.usaqcorp.com

Who is USAQ

USA Equities Corp (OTCMKTS:USAQ) engages in the provision of medical device technology and software as a services. 

It focuses on enabling primary care physicians to increase their revenues by providing them with relevant, value-based tools to evaluate, and treat chronic disease through reimbursable procedures. Its products will enable physicians to diagnose and treat patients with chronic diseases which they historically have referred to specialists. 

Given the skyrocketing costs associated with acute and chronic care in a centralized healthcare model, this revolutionary shift has the potential to contribute to powerful gains in cost and care efficiencies.

According to the company, “Our products improve clinical outcomes for patients – often saving them the time and expense of a specialist visit while allowing physicians to increase their practice revenue through existing reimbursement codes. We provide our clients with the software and training necessary to improve clinical outcomes using value-based healthcare, informatics, and algorithmically personalized medicine to manage behavior-based, remote patient monitoring, chronic care, and preventive medicine.”

On December 20, 2019, USA Equities Corp completed a share exchange whereby it acquired Medical Practice Income, Inc. (MPI). The Company is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. 

The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population. 

According to recent company communications, USAQ is projecting entry level monthly subscriptions will be $299/month or $3,588 per year. Its near-term projection is to acquire 5,000 physician clients by the end of 2023 and over 20,000 physicians in the medium to longer term, which is still less than five percent of the total target physician audience in the US today. 

According to the Journal of Pharma and Healthcare: “There are over 450,000 primary care physicians, including licensed nurse practitioners, in the United States.” 

With a range between $3,588 – $10,000 per physician per year, USAQ is targeting an addressable annual market of roughly $1.6 billion. Capturing just 5% of this market would generate revenue of at least $87 million.

The company’s near-term objective is to acquire five thousand physicians by 2023, which would generate $17.9 million on the topline. All current and future products and services will be sold through the same distribution channel and customer base allowing it to generate additional revenue without the customer acquisition cost. 

Additional future distribution channels will come from licensed nurse practitioners starting their own private practices, walk-up clinics at pharmacies, urgent care clinics in grocery stores, and workplace health clinics for the large self-insured employers seeking healthcare cost savings by providing their employees with cost effective access to primary health care at their place of work. 

For a more in-depth profile, the company was recently featured in an audio podcast on SmallCapVoice.com, which can be accessed here.

Recent Catalysts

Positive Coverage. Most recently, the company announced the publication of a research report on USAQ by global research firm, Litchfield Hills Research LLC. The report, which was accessible on Bloomberg, FactSet, NASDAQ, NYSE Connect, S&P Cap IQ, Thomson Reuters (Refinitiv) and 12 other platforms around the globe, rated the Company a “Buy” under its three-tiered (buy-hold-sell) rating system, with a target price of $5.00 per share.

“Litchfield Hills research report highlights the strong sequential improvement in revenue and gross margin we saw in our first quarter financial results. We have made significant progress over the past few months with the commercial launch of AllergiEnd®’s allergy diagnostic and Allergen immunotherapy products expansion of our management team and visibility in the industry among primary care physicians. We continue to expect an increase in revenue and gross margin in the second quarter of 2021,” said Troy Grogan, CEO of USA Equities Corp.

Booming Growth. The company also recently announced results from a breakout quarter of growth during the 3-months ended March 31, 2021, including strong sequential growth and expectations for the second quarter.

“We made excellent progress executing on our financial and strategic priorities in the first quarter of 2021,” stated USAQ Chief Executive Officer Troy Grogan. “On a sequential basis, our revenue more than doubled to approximately $304,000, while gross margin improved 370 basis points to 43.9%. This growth is due to increased sales of allergy diagnostic kits and immunotherapy treatments as well as expansion of our customer base We also saw continued momentum in April, and currently expect an increase in revenue and gross margin in the second quarter of 2021.”

Expanding Braintrust. The company also recently announced that it has appointed Mr. Mike Mangus to its advisory and physician network development team. Mike will provide strategic guidance in the expansion of the Company’s physician network in conjunction with the Company’s automated cloud-based SaaS digital medicine and virtual care system.

“Mike has shown an invaluable depth of experience in the medical device and technology industry. His demonstrated business and physician network development at previous fortune 1,000 medical companies is expected to be an important contribution to the next phase of commercialization of our digital medicine and virtual care technologies at USAQ,” said Troy Grogan, President and CEO at USA Equities Corp.

This is important given the company’s strong guidance and objectives around expanding its physician network to drive accelerating growth over coming quarters.

Technical Analysis

USAQ has been tracing out a very large Bullish Ascending Triangle breakout pattern for the better part of the past two years. The rule of thumb among technical analysts is: the longer such a triangle breakout pattern has been building, the more explosive its eventual breakout stands to be, potentially.

Nothing in life is remotely guaranteed, and anything is possible in markets.

But, no matter how you slice it, this type of pattern is often very promising. A clear breakout and close above $0.70 would be the trigger for the pattern, in theory.

About USAQ

USAQ (USA Equities Corp) is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care, and preventive medicine. 

The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. 

The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. 

Its principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic, and cardiovascular disease population.

Key Points:

  • USAQ drove strong topline growth in Q1, with revs topping $300k, representing whopping q/q sequential growth of 144%
  • USAQ gross margin improved 370 basis points to 43.9% in Q1
  • USAQ has seen breakout sales of its Allergy Diagnostic Kits and Immunotherapy Treatments to start 2021
  • USAQ also recently projected another sequential increase in Gross Margin in Q2 2021
  • USAQ just recorded a MACD Bullish reversal, suggesting a technical change in trend.
  • USAQ is positioning itself as a leader in core technology aligned with the powerful healthcare decentralization trend, which is rounding the shoulder of an apparently exponential growth curve in developed countries

Conclusion

USAQ is an impressive small-cap in an impressive industry context. The drive to find new disruptive innovations that help scale powerful healthcare treatment solutions with improved outcomes, a wider footprint, and better unit economics at the provider level has taken root and depends on new technology solutions such as those on offer from this innovative name.

Recent results prove the model to some extent, as USAQ sees very strong growth across core metrics and establishes a realistic growth plan with achievable but impressive objectives for coming quarters.

The company is squaring off with a large and growing total addressable market and making rapid strides toward top positioning in its niche.

And, technically, USAQ shares are locked in a clear “Bullish Ascending Triangle” pattern that potentially points to breakout upside action ahead.

 

Recent Chart Activity

The post USAQ: Strong Fundamental Growth, Strong Industry Trends, and Strong Technicals Line Up appeared first on Wall Street PR.

Read More

Related Topics:
Continue Reading

Uncategorized

Part 1: Current State of the Housing Market; Overview for mid-March 2024

Today, in the Calculated Risk Real Estate Newsletter: Part 1: Current State of the Housing Market; Overview for mid-March 2024
A brief excerpt: This 2-part overview for mid-March provides a snapshot of the current housing market.

I always like to star…

Published

12 mins ago

on

March 13, 2024

By

Today, in the Calculated Risk Real Estate Newsletter: Part 1: Current State of the Housing Market; Overview for mid-March 2024

A brief excerpt:
This 2-part overview for mid-March provides a snapshot of the current housing market.

I always like to start with inventory, since inventory usually tells the tale!
...
Here is a graph of new listing from Realtor.com’s February 2024 Monthly Housing Market Trends Report showing new listings were up 11.3% year-over-year in February. This is still well below pre-pandemic levels. From Realtor.com:

New Listings
However, providing a boost to overall inventory, sellers turned out in higher numbers this February as newly listed homes were 11.3% above last year’s levels. This marked the fourth month of increasing listing activity after a 17-month streak of decline.
Note the seasonality for new listings. December and January are seasonally the weakest months of the year for new listings, followed by February and November. New listings will be up year-over-year in 2024, but we will have to wait for the March and April data to see how close new listings are to normal levels.

There are always people that need to sell due to the so-called 3 D’s: Death, Divorce, and Disease. Also, in certain times, some homeowners will need to sell due to unemployment or excessive debt (neither is much of an issue right now).

And there are homeowners who want to sell for a number of reasons: upsizing (more babies), downsizing, moving for a new job, or moving to a nicer home or location (move-up buyers). It is some of the “want to sell” group that has been locked in with the golden handcuffs over the last couple of years, since it is financially difficult to move when your current mortgage rate is around 3%, and your new mortgage rate will be in the 6 1/2% to 7% range.

But time is a factor for this “want to sell” group, and eventually some of them will take the plunge. That is probably why we are seeing more new listings now.
There is much more in the article.

Read More

Continue Reading

Government

RFK Jr. Reveals Vice President Contenders

RFK Jr. Reveals Vice President Contenders

Authored by Jeff Louderback via The Epoch Times,

New York Jets quarterback Aaron Rodgers and former…

Published

43 mins ago

on

March 13, 2024

By

RFK Jr. Reveals Vice President Contenders

Authored by Jeff Louderback via The Epoch Times,

New York Jets quarterback Aaron Rodgers and former Minnesota governor and professional wrestler Jesse Ventura are among the potential running mates for independent presidential candidate Robert F. Kennedy Jr., the New York Times reported on March 12.

Citing “two people familiar with the discussions,” the New York Times wrote that Mr. Kennedy “recently approached” Mr. Rodgers and Mr. Ventura about the vice president’s role, “and both have welcomed the overtures.”

Mr. Kennedy has talked to Mr. Rodgers “pretty continuously” over the last month, according to the story. The candidate has kept in touch with Mr. Ventura since the former governor introduced him at a February voter rally in Tucson, Arizona.

Stefanie Spear, who is the campaign press secretary, told The Epoch Times on March 12 that “Mr. Kennedy did share with the New York Times that he’s considering Aaron Rodgers and Jesse Ventura as running mates along with others on a short list.”

Ms. Spear added that Mr. Kennedy will name his running mate in the upcoming weeks.

Former Democrat presidential candidates Andrew Yang and Tulsi Gabbard declined the opportunity to join Mr. Kennedy’s ticket, according to the New York Times.

Mr. Kennedy has also reportedly talked to Sen. Rand Paul (R-Ky.) about becoming his running mate.

Last week, Mr. Kennedy endorsed Mr. Paul to replace Sen. Mitch McConnell (R-Ky.) as the Senate Minority Leader after Mr. McConnell announced he would step down from the post at the end of the year.

CNN reported early on March 13 that Mr. Kennedy’s shortlist also includes motivational speaker Tony Robbins, Discovery Channel Host Mike Rowe, and civil rights attorney Tricia Lindsay. The Washington Post included the aforementioned names plus former Republican Massachusetts senator and U.S. Ambassador to New Zealand and Samoa, Scott Brown.

In April 2023, Mr. Kennedy entered the Democrat presidential primary to challenge President Joe Biden for the party’s 2024 nomination. Claiming that the Democrat National Committee was “rigging the primary” to stop candidates from opposing President Biden, Mr. Kennedy said last October that he would run as an independent.

This year, Mr. Kennedy’s campaign has shifted its focus to ballot access. He currently has qualified for the ballot as an independent in New Hampshire, Utah, and Nevada.

Mr. Kennedy also qualified for the ballot in Hawaii under the “We the People” party.

In January, Mr. Kennedy’s campaign said it had filed paperwork in six states to create a political party. The move was made to get his name on the ballots with fewer voter signatures than those states require for candidates not affiliated with a party.

The “We the People” party was established in five states: California, Delaware, Hawaii, Mississippi, and North Carolina. The “Texas Independent Party” was also formed.

A statement by Mr. Kennedy’s campaign reported that filing for political party status in the six states reduced the number of signatures required for him to gain ballot access by about 330,000.

Ballot access guidelines have created a sense of urgency to name a running mate. More than 20 states require independent and third-party candidates to have a vice presidential pick before collecting and submitting signatures.

Like Mr. Kennedy, Mr. Ventura is an outspoken critic of COVID-19 vaccine mandates and safety.

Mr. Ventura, 72, gained acclaim in the 1970s and 1980s as a professional wrestler known as Jesse “the Body” Ventura. He appeared in movies and television shows before entering the Minnesota gubernatorial race as a Reform Party headliner. He was a longshot candidate but prevailed and served one term.

Former pro wrestler Jesse Ventura in Washington on Oct. 4, 2013. (Brendan Smialowski/AFP via Getty Images)

In an interview on a YouTube podcast last December, Mr. Ventura was asked if he would accept an offer to run on Mr. Kennedy’s ticket.

“I would give it serious consideration. I won’t tell you yes or no. It will depend on my personal life. Would I want to commit myself at 72 for one year of hell (campaigning) and then four years (in office)?” Mr. Ventura said with a grin.

Mr. Rodgers, who spent his entire career as a quarterback for the Green Bay Packers before joining the New York Jets last season, remains under contract with the Jets. He has not publicly commented about joining Mr. Kennedy’s ticket, but the four-time NFL MVP endorsed him earlier this year and has stumped for him on podcasts.

The 40-year-old Rodgers is still under contract with the Jets after tearing his Achilles tendon in the 2023 season opener and being sidelined the rest of the year. The Jets are owned by Woody Johnson, a prominent donor to former President Donald Trump who served as U.S. Ambassador to Britain under President Trump.

Since the COVID-19 vaccine was introduced, Mr. Rodgers has been outspoken about health issues that can result from taking the shot. He told podcaster Joe Rogan that he has lost friends and sponsorship deals because of his decision not to get vaccinated.

Quarterback Aaron Rodgers of the New York Jets talks to reporters after training camp at Atlantic Health Jets Training Center in Florham Park, N.J., on July 26, 2023. (Rich Schultz/Getty Images)

Earlier this year, Mr. Rodgers challenged Kansas City Chiefs tight end Travis Kelce and Dr. Anthony Fauci to a debate.

Mr. Rodgers referred to Mr. Kelce, who signed an endorsement deal with vaccine manufacturer Pfizer, as “Mr. Pfizer.”

Dr. Fauci served as director of the National Institute of Allergy and Infectious Diseases from 1984 to 2022 and was chief medical adviser to the president from 2021 to 2022.

When Mr. Kennedy announces his running mate, it will mark another challenge met to help gain ballot access.

“In some states, the signature gathering window is not open. New York is one of those and is one of the most difficult with ballot access requirements,” Ms. Spear told The Epoch Times.

“We need our VP pick and our electors, and we have to gather 45,000 valid signatures. That means we will collect 72,000 since we have a 60 percent buffer in every state,” she added.

The window for gathering signatures in New York opens on April 16 and closes on May 28, Ms. Spear noted.

“Mississippi, North Carolina, and Oklahoma are the next three states we will most likely check off our list,” Ms. Spear added. “We are confident that Mr. Kennedy will be on the ballot in all 50 states and the District of Columbia. We have a strategist, petitioners, attorneys, and the overall momentum of the campaign.”

Tyler Durden Wed, 03/13/2024 - 15:45

Read More

Continue Reading

Uncategorized

Pharma industry reputation remains steady at a ‘new normal’ after Covid, Harris Poll finds

The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45%…

Published

3 hours ago

on

March 13, 2024

By

The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45% of US respondents in 2023, according to the latest Harris Poll data. That’s exactly the same as the previous year.

Pharma’s highest point was in February 2021 — as Covid vaccines began to roll out — with a 62% positive US perception, and helping the industry land at an average 55% positive sentiment at the end of the year in Harris’ 2021 annual assessment of industries. The pharma industry’s reputation hit its most recent low at 32% in 2019, but it had hovered around 30% for more than a decade prior.

Rob Jekielek

“Pharma has sustained a lot of the gains, now basically one and half times higher than pre-Covid,” said Harris Poll managing director Rob Jekielek. “There is a question mark around how sustained it will be, but right now it feels like a new normal.”

The Harris survey spans 11 global markets and covers 13 industries. Pharma perception is even better abroad, with an average 58% of respondents notching favorable sentiments in 2023, just a slight slip from 60% in each of the two previous years.

Pharma’s solid global reputation puts it in the middle of the pack among international industries, ranking higher than government at 37% positive, insurance at 48%, financial services at 51% and health insurance at 52%. Pharma ranks just behind automotive (62%), manufacturing (63%) and consumer products (63%), although it lags behind leading industries like tech at 75% positive in the first spot, followed by grocery at 67%.

The bright spotlight on the pharma industry during Covid vaccine and drug development boosted its reputation, but Jekielek said there’s maybe an argument to be made that pharma is continuing to develop innovative drugs outside that spotlight.

“When you look at pharma reputation during Covid, you have clear sense of a very dynamic industry working very quickly and getting therapies and products to market. If you’re looking at things happening now, you could argue that pharma still probably doesn’t get enough credit for its advances, for example, in oncology treatments,” he said.

Read More

Continue Reading

Trending